TherapeuticsMD (TXMD) Misses Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
TherapeuticsMD (TXMD) Appoints Hugh O’Dowd as CEO
November 11, 2021 6:45 AM ESTTherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading womens healthcare company, today announced key leadership changes, including the appointment of Hugh ODowd, the Companys current President, as the Companys Chief Executive Officer and member of the board of directors. Mr. ODowd will succeed Robert G. Finizio, the Companys Co-founder and current Chief Executive Officer, effective on or before December 31, 2021. Mr. Finizio will continue with the Company and has been appointed Vice Chair of the Board of Directors.
I want to thank Rob for his strong leadership and vision over the past 13... More
